Healthcare Finance Staff
When I saw Paying for the Thousand-Dollar Pill, an anti-Sovaldi op-ed in the Wall Street Journal, it brought back memories from my childhood when I toured the FBI headquarters in Washington, DC. The tour guide started off by showing us a wall with pictures of the 10 most wanted fugitives in the country and asked for our help in tracking them down.
Insurers may need to find new ways to control costs for specialty drugs, as more states add limits to cost-sharing and utilization continues to grow.
From a real estate perspective, the healthcare landscape is dramatically changing. The massive, monolithic structures that have come to represent the acute care setting are becoming more stratified in smaller buildings across wider swaths of a community.
Among providers trying to get into the insurance game, some are starting off small at the local level, but in a big, growing market segment.
The way blood-based diagnostic tests are performed and paid for could change dramatically if a new company has its way, with the potential to benefit patients and payers at the expense of traditional providers.
In the debate over provider networks, broad access has been the goal of many patient advocates, but some are also warning of unintended consequences of over-regulation.
The Affordable Care Act is boosting short-term finances for insurers and providers alike. Long-term, though, traditional business models appear untenable and health organizations must evolve to remain sustainable.
Our weekly look at career moves in the healthcare finance sector. This issue highlights promotions, hires and fires for the week ending August 15, 2014.
A once-promised truth in pharmaceutical benefits management is unravelling, leaving payers exposed and researchers scratching their heads.
Walmart's potential impact on healthcare is far greater than creating more primary care clinics or becoming just another health plan.